CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary SMART linker technology platform, today announced that it has named Rick Modi as chief business officer. Mr. Modi brings to Catabasis 15 years of experience in corporate, business and product commercialization strategy.
“Rick has valuable experience across multiple brands, including orphan drug positioning, commercialization and marketing,” said Jill C. Milne, Ph.D., co-founder and chief executive officer of Catabasis. “We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid programs, CAT-2003 and CAT-2054.”
“Catabasis has a novel approach to drug development that allows for simultaneous modulation of multiple targets in a disease pathway, and I am privileged to join this team as we seek to bring disease-modifying treatments to patients with DMD or severe lipid disorders,” commented Mr. Modi.
Prior to joining Catabasis, Mr. Modi was senior vice president, global marketing at InterMune, an orphan drug company that was acquired by Roche in 2014. He played a pivotal role in the launch of InterMune’s flagship product, Esbriet. Rick also held roles of increasing responsibilities in corporate strategy, new product planning and sales and marketing at MedImmune (AstraZeneca) and Centocor (Johnson & Johnson). Rick holds an MBA from the Wharton School and a BS in pharmacy from the University of Iowa.
About Catabasis
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The company's SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The company’s initial focus is on treatments for orphan diseases. The company is also developing other product candidates for the treatment of serious lipid disorders. For more information on the Company's technology and pipeline of drug candidates, please visit www.catabasis.com.
